Hillstream BioPharma Announces Participation in the Biotech Showcase’s PartneringOne® System and Availability for Outside Appointments

January 2, 2020

Chester, New Jersey, January 2, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in the Biotech Showcase™’s one-to-one meeting system, partneringOne®.  The event will run from January 13-16, 2020.  One-on-one meetings booked through the partneringONE® system will be held at the Hilton San Francisco Union Square.

Additionally, investors wishing to meet with Hillstream outside of the Biotech Showcase’s one-on-one system can book appointments directly through Hillstream’s investor relations representative, Jennifer K. Zimmons, Ph.D.

Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in 1H-2020.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

About Hillstream BioPharma Inc.

Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company advancing improved therapies for patients with cancer via a unique QUATRAMER nanoparticle delivery platform. This unique technology enables intranuclear and intracellular delivery of small molecules, peptides, genes, other macromolecules and biologics to the tumor cello, while significantly minimizing exposure to normal tissues.  Hillstream’s competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in its proprietary polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek both FDA Orphan Drug Designation and more rapid FDA review in specific indications.  For more information, please visit tharimmune.com.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.


Hillstream BioPharma Inc.
Randy Milby
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Email: rmilby@tharimmune.com

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com